Company: BLCO
Filing Date: 2025-06-10
Form Type: 8-K
Source: 0000950103-25-007189
Chunk: 0

Company: Bausch & Lomb Corp
Filing Date: 2025-06-10
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

Secured Notes Offering

On June 10, 2025, Bausch + Lomb Corporation (the
“ Company” or “ Bausch + Lomb”) announced that its subsidiaries, Bausch & Lomb Incorporated, a New York corporation
(the “ U. S. Co-Issuer”), and Bausch+Lomb Netherlands B. V. a private company with limited liability ( besloten vennootschap
met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (the “ Dutch Co-Issuer” and, together with
U. S. Co-Issuer, the “ Issuers”), launched an offering of €600 million aggregate principal amount of senior secured floating rate notes (the “ Notes”).

Substantially concurrently with the Notes
offering, the Company launched a partial refinancing of its credit agreement, whereby the Company intends to obtain a $2.2 billion
new term B loan facility (the “ New Term B Loan Facility”) and a new $800 million revolving credit facility (the
“ New Revolving Credit Facility”). The Company intends to use the net proceeds from the Notes offering and the New Term B
Loan Facility, together with borrowings under the New Revolving Credit Facility, to repay certain outstanding
borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans
due 2027, and to pay related fees and expenses, with any remaining amounts to be used for general corporate purposes.

The closing of the Notes offering is not contingent
upon the closing the New Term B Loan Facility or the New Revolving Credit Facility.

The Notes will be guaranteed by the Company and
each of the Company's subsidiaries (other than the Issuers) that are guarantors under the Company's credit agreement and will be secured
on a first priority basis by liens on the same assets that secure the obligations under the Company's credit agreement and the Company's
8.375% senior secured notes due 2028.

The foregoing transactions are subject to market
and other conditions. There can be no assurance that the Company will be able to successfully complete the transactions on the terms described
above, or at all.

The Notes are being offered in the United States
to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
(the “ Securities